Overview
- Britain’s medicines regulator has authorized Eli Lilly’s oral GLP‑1 tablet Foundayo for weight management and some patients with type 2 diabetes, clearing the way for private sales in the UK.
- Routine NHS coverage is not yet in place because the drug must pass a cost‑effectiveness assessment by NICE before broader public reimbursement is granted later this year.
- Clinical data from the ATTAIN‑1 program cited by Lilly showed substantial weight loss on the 36 mg dose compared with placebo over the trial period, supporting the approval.
- Foundayo joins an existing private‑market oral option from Novo Nordisk and will compete on convenience, side‑effect profile, pricing and manufacturing supply to win prescribing share.
- Lilly is pursuing a multi‑product obesity strategy that includes injectable Zepbound, next‑generation retatrutide and the non‑GLP‑1 candidate eloralintide, a push that shapes investor expectations and the company’s need to scale production and manage prices.